Advaxis, Inc. (ADXS) Presenting at Biotech Showcase 2014

Today before the opening bell, Advaxis announced that it will be presenting at the Biotech Showcase 2014 Conference in San Francisco, California. The conference will be taking place at the Parc 55 Wyndham San Francisco Union Square Hotel from Monday, January 13, 2014 to Wednesday, January 15, 2014.

Mr. Daniel J. O’Connor, the CEO of Advaxis, will be presenting a corporate update at 11:30 am PST (Pacific Time) on Wednesday, January 14, 2014. Aside from on-site attendance, onlookers can watch the presentation along with a slide presentation at: http://www.media-server.com/m/p/nzctmxk8.

Advaxis is a clinical-stage, publicly held biotechnology company that is focusing on developing next-generation cancer immunotherapies. All of the company’s immunotherapeutic innovations are based upon a unique platform using live, attenuated bacteria that secrete an antigen/adjuvant fusion protein(s). These proteins, in turn, are designed to redirect the powerful immune response all human beings have to the bacterium to a cancer itself. Currently, Advaxis has over 15 immunotherapies in various stages of development. The company’s lead drug candidate, ADXS-HPV, is in multiple clinical trials for HPV-related cancers.

For more information, visit: www.advaxis.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html